ACT Stock UPDATES Actavis Inc (ACT) 215.77 08/04/2014 20:55:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actavis Inc (ACT) 215.77 $ACT

Jim Cramer's 'Mad Money' Recap: Watch Your Back
at The Street - 1 hr 56 mins ago
Forget what the pundits say, the real reason for the market's turmoil remains Russia, Cramer says.

Earnings Releases, Technical Updates, FDA Acceptances, and New Products - Research Reports on Newfield Exploration, YPF, HCA, Actavis and 3M
PR Newswire - Mon Aug 04, 7:50AM CDT
Today, Analysts Review released its research reports regarding Newfield Exploration Company (NYSE: NFX), YPF SA (NYSE: YPF), HCA Holdings Inc (NYSE: HCA), Actavis plc (NYSE: ACT) and 3M Company (NYSE: MMM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5394-100free.

Why Actavis (ACT) Might Surprise This Earnings Season - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 7:36AM CDT
Actavis has been witnessing a positive momentum in the earnings estimate front and possess a favorable Zacks Rank

Salix, Actavis Lead IBD 50 Drug Earnings This Week
at Investor's Business Daily - Sat Aug 02, 7:02AM CDT
Salix Pharmaceuticals (SLXP), which announced its tax inversion merger last month, will be among several IBD 50 drug stocks to report earnings this week. In July, Salix announced plans to merge with Italy's Cosmo Pharmaceuticals' Irish subsidiary,...

Endo International Beats on Q2 Earnings & Sales, Guidance Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:36PM CDT
Endo (ENDP) reported higher-than-expected earnings and revenues in the quarter.

Many Leading Stocks Damaged As Market Tumbles Broadly
at Investor's Business Daily - Thu Jul 31, 1:51PM CDT
The stock market remained sharply lower in afternoon trading, a sell-off worsened by the many leading stocks coming under attack. The Nasdaq tumbled 1.6%, the S&P 500 1.4% and the Dow Jones industrial average 1.3%. The small-cap Russell 2000 skidded...

3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.

Tax Inversion Puts These 3 Mutual Funds in Focus - Best of Funds
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 1:38PM CDT
The trend of tax inversion has been mostly prevalent in the healthcare sector. Medical devices and pharma companies are rapidly buying foreign competitors. Mutual funds holding these stocks in their portfolio should thus experience solid uplift in the near term.

Actavis May Give Buyers Another Chance
at Investor's Business Daily - Mon Jul 28, 5:03PM CDT
Drugmaker Actavis broke out of a cup-with-handle base June 18 but hasn't made much headway since then. It's slightly below a 216.80 buy point, struggling for support at its 50-day moving average. But it might be building a new handle and could make...

Is Teva Pharmaceuticals Stock Really Your Best Generic Drug Investment Option?
Brian Nichols, The Motley Fool - Motley Fool - Thu Jul 24, 7:54AM CDT
UBS made news over the weekend with its list of six stocks that could soar behind key catalysts not priced into each respective company. Within that list is Teva Pharmaceuticals , a company that UBS believes will benefit from continued patent...

Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook

Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Thu Jul 24, 2:47AM CDT
Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Zacks Analyst Interviews

World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others) 2013-2017
M2 - Wed Jul 23, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpvpdw/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - Biosimilars Pipeline by Company and Product Type - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/tp...rld_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Medicines360 and Actavis files Levosert IUD's NDA for US FDA's substantive review
M2 - Tue Jul 22, 8:15AM CDT
Pharmaceutical company Medicines360 disclosed on Monday that the US Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for Levosert in partnershp with Actavis (NYSE:ACT).

Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for Levosert(TM) IUD
PR Newswire - Mon Jul 21, 3:30PM CDT
Medicines360, a non-profit women's health pharmaceutical company, and Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360's New Drug Application (NDA) for Levosert(TM) (levonorgestrel), a hormonal intrauterine contraceptive (IUC) for use by women to prevent pregnancy.

Synergy Pharmaceuticals Progresses with Mid-Stage Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 5:15PM CDT
Synergy Pharmaceuticals (SGYP) completed patient enrollment for its phase II study on SP-333.

Enable Partners, Other Leaders Facing Market Pressure
at Investor's Business Daily - Fri Jul 18, 5:10PM CDT
When the market is under pressure, stocks often face a tougher time following through on breakouts, and this time around is no exception. Actavis (ACT), Concho Resources (CXO) and Enable Midstream Partners (ENBL) are among leading Spotlight stocks...

Glance: Biggest corporate deals so far this year
By The Associated Press - AP - Fri Jul 18, 10:58AM CDT
Abbvie Inc.'s deal to combine with Shire PLC would be the largest made so far this year, excluding assumed debt. Here are the top five:

Mylan (MYL) Joins the Tax-Inversion Wave - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Jul 16, 12:03PM CDT
More M&A activity involving tax-inversion can be expected in the days ahead.

Facebook, Apple Suppliers Lead 5 Big-Cap All-Stars
at Investor's Business Daily - Wed Jul 16, 8:16AM CDT
Looking for Wall Street's stock all-stars? IBD's Screen of the Day is Big Cap Leaders, which includes the top-performing large-cap stocks with strong fundamentals and technicals. This article focuses on the screen's five companies including social...



Scroll down for more posts ▼

Top 10 Most Recent News Articles

DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 186

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 775

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 414

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 94

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 502

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 179

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 106

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 114

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading

Top 5 Most Recently Viewed Articles

Aitech Honored for Its Breakthrough in Rugged AI Technology

Updated Category News Views 382

Aitech Secures 2025 Artificial Intelligence Excellence Award Aitech, renowned for its rugged embedded systems tailored for military, aerospace, and space applications, has recently been distinguished as a winner in the 2025 Artificial Intelligence Excellence Awards organized by the Business Intelligence Group. This accolade celebrates the innovative strides in AI and...

Continue Reading
National Hydropower Association Emphasizes Hydropower's Importance

Updated Category News Views 129

National Hydropower Association Celebrates Hydropower Day The National Hydropower Association (NHA), the foremost trade association for the water power industry in the U.S., is excited to celebrate National Hydropower Day. This annual event pays tribute to the water power sector and the dedicated American workers who contribute to this essential renewable resource. The...

Continue Reading
Changing Perspectives: German Parents Embrace Cannabis Cultivation

Updated Category News Views 269

Changing Perspectives on Cannabis in Germany In Germany, the landscape of cannabis use has transformed remarkably in the past year. With the legislation on cannabis legalization now in effect, the cultural and social dynamics are evolving. Although there are mixed feelings on the topic, it's evident that younger people, particularly parents, are leaning towards supporting...

Continue Reading
Select Water Solutions Unveils 2025 Q1 Earnings Event Details

Updated Category News Views 257

Select Water Solutions Announces 2025 First Quarter Earnings Select Water Solutions, Inc. (NYSE: WTTR) is gearing up for the announcement of its financial performance for the first quarter of 2025. The company has confirmed the release date of these results, which is set to take place after the market closes on an upcoming Tuesday. This is an exciting time for investors...

Continue Reading
Colabor Group's Strategic Moves Shape Future Financial Outlook

Updated Category News Views 183

Colabor Group's Financial Performance Overview Colabor Group Inc. (TSX: GCL) reveals its financial results for the fourth quarter and fiscal year, providing insights into its ongoing market performance. Fourth Quarter Highlights In the fourth quarter, Colabor Group demonstrated resilience with a sales increase of 3.2%, reaching $202.6 million. Comparatively, sales were at...

Continue Reading